GlassScriptPhysician profile
Lauren Fill
NPI 1669969697
$7,114.10
in general payments reported to CMS, 2019-2025
31 companies · $3,036 in 2025
The $3,036 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $544 · 2023: $1,580 · 2024: $1,803 · 2025: $3,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,257 · Education: $104 · Consulting Fee: $58.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,256.64 |
| Education | $103.59 |
| Consulting Fee | $58.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,408.59 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $900.59 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $802.61 | 2021-2025 | Dupixent |
| Csl Behring | $740.74 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $582.69 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $452.84 | 2023-2025 | |
| Amgen INC. | $401.77 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $234.89 | 2021-2025 | Gamunex-C, Xembify, Prolastin-C Liquid |
| Pfizer INC. | $214.57 | 2023-2025 | |
| Genentech USA, INC. | $199.90 | 2023-2025 | Xolair |
| Blueprint Medicines Corporation | $170.93 | 2023-2024 | Ayvakit |
| Optinose US, INC. | $133.20 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $123.10 | 2023-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $114.43 | 2022-2025 | Glassia, Hyqvia, Aralast |
| Phadia US INC. | $96.86 | 2023-2025 | Immunocap |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $82.70 | 2021-2023 | Auvi-Q |
| Octapharma USA, INC. | $78.77 | 2022-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Adma Biomanufacturing LLC | $58.55 | 2025 | |
| Incyte Corporation | $51.62 | 2023-2024 | Opzelura |
| Abbvie INC. | $44.34 | 2022-2023 | |
| Jubilant Hollisterstier LLC | $38.88 | 2024-2025 | |
| Ionis Pharmaceuticals, INC. | $24.33 | 2025 | Dawnzera |
| Horizon Therapeutics Plc | $20.60 | 2022 | |
| Pharming Healthcare, INC. | $19.72 | 2025 | Ruconest |
| Lilly USA, LLC | $18.80 | 2025 | Ebglyss |
| Aytu Biopharma, INC. | $18.80 | 2024 | Karbinal |
| Organon LLC | $18.57 | 2023 | Renflexis |
| Azurity Pharmaceuticals, INC. | $17.90 | 2025 | Alvesco |
| Galderma Laboratories, L.P. | $16.20 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $15.99 | 2025 | Sajazir |
| Bio Products Laboratory USA, INC. | $10.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Fill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.